China SXT Pharmaceuticals Inc Cash Flow-to-Debt Ratio
China SXT Pharmaceuticals Inc cash flow-to-debt ratio. China SXT Pharmaceuticals Inc (SXTC) has a Cash Flow-to-Debt Ratio of -0.45x as of June 2026, meaning its operating cash flow of $-2.26 Million could theoretically repay 0% of its total liabilities ($5.05 Million) in one year. Check earnings quality score of China SXT Pharmaceuticals Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of China SXT Pharmaceuticals Inc (2016–2026)
Cash flow-to-debt ratio of China SXT Pharmaceuticals Inc from 2016 to 2026. Historical debt coverage capacity for China SXT Pharmaceuticals Inc across 11 annual periods. Check China SXT Pharmaceuticals Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
China SXT Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2016–2026)
China SXT Pharmaceuticals Inc cash flow-to-debt ratio by year from 2016 to 2026. Year-by-year debt coverage analysis for China SXT Pharmaceuticals Inc. For the full cash flow conversion analysis, see China SXT Pharmaceuticals Inc cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | -0.80x | $-4.02 Million | $5.05 Million | ▼ -111.2% |
| 2025 | -0.38x | $-2.35 Million | $6.22 Million | ▼ -79.7% |
| 2024 | -0.21x | $-1.93 Million | $9.20 Million | ▼ -3758.4% |
| 2023 | -0.01x | $-80.76K | $14.86 Million | ▲ +96.1% |
| 2022 | -0.14x | $-2.37 Million | $17.12 Million | ▼ -95.8% |
| 2021 | -0.07x | $-1.32 Million | $18.59 Million | ▼ -193.3% |
| 2020 | 0.08x | $934.25K | $12.30 Million | ▲ +102.0% |
| 2019 | 0.04x | $239.19K | $6.36 Million | ▼ -91.4% |
| 2018 | 0.44x | $1.92 Million | $4.37 Million | ▲ +436.4% |
| 2017 | 0.08x | $293.04K | $3.58 Million | ▲ +149.2% |
| 2016 | 0.03x | $182.47K | $5.55 Million | — |